BrainsWay's Deep TMS Coverage Expands to Over 57 Million Lives
Summary
BrainsWay announced a significant expansion of favorable insurance coverage for its SWIFT™ Accelerated Deep TMS™ protocol, now reaching over 57 million covered lives across major U.S. payers and the VA.
Key Events
-
Expanded Insurance Coverage
Favorable medical policies for BrainsWay's SWIFT™ Accelerated Deep TMS™ protocol now cover over 57 million lives across the U.S.
-
New Policy Addition
A recently issued policy in South Carolina adds 2 million members to the covered population for SWIFT™ Deep TMS™.
-
Broad Payer Support
Eight major payers and the U.S. Department of Veterans Affairs now either cover or include policy language supporting accelerated TMS treatment approaches.
-
Improved Patient Access
This expansion improves patient access to Deep TMS therapies for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
Analysis
This filing details a substantial increase in market access for BrainsWay's key Deep TMS therapy, particularly its accelerated SWIFT protocol. The expansion to over 57 million covered lives, including a new policy in South Carolina, directly enhances the company's revenue potential by making its treatments accessible to a much larger patient population. This reinforces the company's commercial momentum and reduces reimbursement hurdles, which are critical for medical device adoption.
At the time of this filing, BWAY was trading at $14.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $582.3M. The 52-week trading range was $5.42 to $17.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.